关键信息
-
基因名
MSLN
- 应用
-
别名
SMR; MPF; CAK1; Pre-pro-megakaryocyte-potentiating factor; Megakaryocyte-potentiating factor
-
种属
Human
-
表达系统
HEK293
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q13421
-
表达区间
Glu296~Ser606
-
分子量
42&46kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
MSLN, or Mesothelin, is a glycoprotein that is overexpressed in several malignancies, including mesothelioma, pancreatic cancer, and ovarian cancer, making it a significant target for cancer immunotherapy. The interest in MSLN has been fueled by its role as a tumor marker and its potential use in targeted therapies, particularly those involving monoclonal antibodies and adoptive T cell therapies. Research on recombinant MSLN proteins has advanced our understanding of its biological functions and its interactions with immune cells. Studies have shown that MSLN can facilitate tumor progression and may modulate the immune response, thereby providing a double-edged sword in cancer biology. The ability to produce recombinant MSLN has enabled the development of novel diagnostic tools and therapeutic agents aimed at harnessing the immune system to combat cancer. By elucidating the structure and function of MSLN, researchers are exploring its application in vaccines and adoptive cell transfer strategies. The therapeutic potential of MSLN-targeted approaches is underscored by ongoing clinical trials evaluating MSLN-specific agents, highlighting the importance of this protein in the quest for more effective cancer treatments. As research continues, MSLN remains a focal point for understanding tumor biology and developing innovative therapeutic interventions.
